Gene · 5693
PSMB5: proteasome 20S subunit beta 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMB5: proteasome 20S subunit beta 5. Genes, record 5693. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5693
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28074 | Proteasome subunit beta type-5 | 263 | 156 | Ensembl, GeneID, HGNC |
Source UniProt
Patents41
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59534 | P28074 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8048 | P28074 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5358 | P28074 | Espacenet |
| US 12433933 B2 | 2025-10-07 | 14 | P28074 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8048 | P28074 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5358 | P28074 | Espacenet |
| JP 2024009871 A | 2024-01-23 | 69 | P28074 | Espacenet |
| US 11771740 B2 | 2023-10-03 | 14 | P28074 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67915 | P28074 | Espacenet |
| JP 2022533303 A | 2022-07-22 | 14 | P28074 | Espacenet |
1 to 10 of 41
See all 41 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants1,004
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMB5 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 10 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 4 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 4 | 2025 |
| P50CA098252 | SPORE in Cervical Cancer | 3 | 2025 |
| R35GM130234 | Chemical Biology of Cell Division | 3 | 2025 |
| T32CA193201 | Integrative Training in Oncogenic Signaling | 3 | 2025 |
| I01BX001584 | Molecular Manipulation to Enhance Anti-Myeloma Response | 2 | 2025 |
| K12HD052896 | Child Health Research Career Development Award (CHRCDA) Program (K12) | 2 | 2025 |
1 to 10 of 1,004Source NIH's project files
See all 1,004 nih grantsPapers1,295
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ultramutagenesis through Combined Msh2 Depletion and Proofreading-Deficient DNA Polymerase ε Expression Enhances Small-Molecule Target Identification in Forward Genetic Screens. | ACS Chem Biol | 2026 | 42723219 | PubTator, text mining | PubMed |
| SADS-CoV Nsp1 hijacks proteasomal subunits to degrade IRF1. | Vet Microbiol | 2026 | 42721780 | PubTator, text mining | PubMed |
| Proteasome Dysfunction in Basal Keratinocytes Drives Epidermal Disruption and Dermal Inflammation. | Am J Pathol | 2026 | 42674183 | PubTator, text mining | PubMed |
| Air pollution and hepatocellular carcinoma: Integrated network toxicology, machine learning, molecular docking and multiomics analysis. | Oncol Lett | 2026 | 42428344 | PubTator, text mining | PubMed |
| Ultramutagenesis through combined Msh2 depletion and proofreading-deficient DNA polymerase ε expression enhances small molecule target identification in forward genetic screens. | bioRxiv | 2026 | 42427792 | PubTator, text mining | PubMed |
| Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial. | Cardiovasc Endocrinol Metab | 2026 | 42367684 | PubTator, text mining | PubMed |
| EphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer. | Cell Death Dis | 2026 | 42362505 | PubTator, text mining | PubMed |
| Proteome Profiling Reveals NQO2 Activity Contributing to Proteasome Inhibitor Resistance in Multiple Myeloma Cell Lines. | Mol Cell Proteomics | 2026 | 42362189 | PubTator, text mining | PubMed |
| Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. | NPJ Precis Oncol | 2026 | 42303761 | PubTator, text mining | PubMed |
| Integrative Pan-Cancer Mapping of Proteasome Dependency Prioritizes PSMB5 and PSMB6 as Context-Dependent Vulnerability Biomarkers Linked to Immune Context. | Molecules | 2026 | 42280256 | PubTator, text mining | PubMed |
1 to 10 of 1,295
See all 1,295 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5693
GET https://conductscience.org/api/genes/v1/5693/patents?page=2